open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Get Citation

Antiangiogenic treatment in patients with non-small cell lung cancer

Maciej Krzakowski

open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29

Abstract

The use of agents addressing angiogenesis may potentially improve outcomes of patients with lung cancer. The results of numerous studies evaluating an antiangiogenic therapy in non-small cell lung cancer are much more promising in comparison with trials in small cell lung cancer. Bevacizumab, a recombinant humanised monoclonal antivascular endothelial growth factor antibody, improved significantly progression- -free and overall survival when combined with platinum-based first-line chemotherapy in selected patients with advanced non-small cell lung cancer. Some toxic effects, particulaly tumor-related bleeding, were associated with the addition of bevacizumab to chemotherapy predominantly in patients with squamous-cell and centrally located tumours. Several small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (eg., sorafenib and sunitinib) are under investigation and early results of the studies justify further research in lung cancer. In general, the value of clinical and molecular predictive markers has to be elucidated given the significant toxicities and costs of antiangiogenic agents. Trials adressing the issue of optimal treatment duration are also mandatory, since current paradigm of continuing antiangigenic therapy until progression or unacceptable toxicity is based on theoretical grounds only.

Abstract

The use of agents addressing angiogenesis may potentially improve outcomes of patients with lung cancer. The results of numerous studies evaluating an antiangiogenic therapy in non-small cell lung cancer are much more promising in comparison with trials in small cell lung cancer. Bevacizumab, a recombinant humanised monoclonal antivascular endothelial growth factor antibody, improved significantly progression- -free and overall survival when combined with platinum-based first-line chemotherapy in selected patients with advanced non-small cell lung cancer. Some toxic effects, particulaly tumor-related bleeding, were associated with the addition of bevacizumab to chemotherapy predominantly in patients with squamous-cell and centrally located tumours. Several small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (eg., sorafenib and sunitinib) are under investigation and early results of the studies justify further research in lung cancer. In general, the value of clinical and molecular predictive markers has to be elucidated given the significant toxicities and costs of antiangiogenic agents. Trials adressing the issue of optimal treatment duration are also mandatory, since current paradigm of continuing antiangigenic therapy until progression or unacceptable toxicity is based on theoretical grounds only.
Get Citation

Keywords

antiangiogenesis; non-small-cell lung cancer; systemic therapy

About this article
Title

Antiangiogenic treatment in patients with non-small cell lung cancer

Journal

Oncology in Clinical Practice

Issue

Vol 5, Supp. A (2009)

Pages

26-31

Published online

2009-04-29

Keywords

antiangiogenesis
non-small-cell lung cancer
systemic therapy

Authors

Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl